Published: January 3, 2016 – 12:27PM
Outsiders don’t want their daughters to marry any local boys, according to the village elders swapping stories in a tailor’s shop behind the Sikh temple, because most residents are infected with “black jaundice”.
That’s what they call hepatitis C, which is so common in parts of India’s Punjab state that the tailor-shop gossips might not be off base in their estimate. But prevalence could be something of an advantage these days.
Drugmakers have made the village of Lande Rode one of the theatres in a battle to grab market share for sofosbuvir, a miracle cure that Gilead Sciences sells in the US as Sovaldi at a retail price of $US1000 ($1200) a pill. Gilead licensed 11 Indian companies to make generic versions, and they sealed marketing deals with others. Competition has been so fierce it’s driven down the cost and spurred thousands to be tested.
Manufacturers “want more and more patients” and are willing to wheel and deal on price, said Nirmaljeet Malhi, a gastroenterologist at Apollo Hospitals in Ludhiana, about 200km from Lande Rode. “If one agrees to it, the others will also have to. It’s a race where one cannot say no – because then they’re going to lose the business.”
The companies sponsor screening drives, hand out free test kits to hospitals and offer bulk discounts to entire villages. Sofosbuvir was cheap by almost any standard when it hit the market in Punjab at $US10 ($12) in March. Then the cost kept dropping, to as low as $US4.29, and doctors predict it will continue to fall.
That’s in contrast to the situation in the US, where Gilead set off a firestorm in December 2013 by listing Sovaldi at $US84,000 ($116,200) for a 12-week course regimen.
It’s a game-changing drug, often wiping out an infection in three months, and without the debilitating side effects of earlier treatments that took longer. Still, the cost started the latest backlash over high medicine prices. Dozens of state Medicaid plans limited access to the drug, and a US Senate report chastised the company. Gilead, which has said it priced Sovaldi responsibly and thoughtfully, is giving insurers and bulk purchasers discounts.
The same drug is available on the pharmaceutical benefits scheme in Australia, costing taxpayers tens of millions of dollars.
Like others in the industry, Gilead arranges to make life-saving cures available in some parts of the world for far less; laws and pressure introduced so-called tiered pricing after expensive anti-HIV treatments became available in the 90s and reduced deaths in rich countries and not poor ones. In exchange for a 7 per cent cut of sales, Gilead gave companies including Mylan, Cipla and Natco Pharma rights to make generics for distribution in 101 developing nations where hepatitis C is often untreated and $US1000 is more than people might earn in a year. The company wants to “foster competition in the marketplace” in low-income areas, according to spokesman Nathan Kaiser.
Now there are more than a dozen sofosbuvir versions for sale in India. “The market has become highly competitive in the last six months with close to 20 companies launching their own,” said MV Ramana, executive vice president and head of branded markets at Dr Reddy’s Laboratories.
The sofosbuvir rivals are aggressive about expanding the customer base by making the pills affordable and diagnosis easier. Dr Reddy’s, for example, set up a venture with lender Arogya Finance to offer no-interest loans for patients, and Abbott Laboratories worked with French medical equipment company Echosens SAS to supply Indian hospitals with 13 ultrasound machines that determine the level of fibrosis, or hardening, without a liver biopsy.
A main benefit of the competition, according to doctors, is that so many are being tested for hepatitis C, which can lead to cirrhosis and liver cancer. As many as 150 million people have the disease, according to the World Health Organisation, including at least 12 million in India. Common modes of transmission are tainted medical equipment and reuse of syringes.
Some of the highest infection rates are in Lande Rode and other villages of Punjab’s cotton-growing Malwa belt, where 30 per cent to 50 per cent of the population might have the virus, said Gagandeep Goyal, a gastroenterologist at Global Healthcare, a hospital sandwiched between an Adidas store and a Vodafone outlet in Bathinda, the fifth-largest city in Punjab.
There are expenses beyond the drug itself. Villagers are encouraged to go to hospitals in cities for exams to determine the amount of virus in the blood and the exact strain, and scans to see the amount of scarring on the liver. At Malhi’s hospital the charge for a liver scan is 3500 rupees ($72.40).
Malhi said pharmaceutical companies might be persuaded to help defray these costs too. “If bulk treatment is required – say, in a village where 200 people are positive – they might give more favourable pricing to that village for complete treatment,” he said. As for the drug itself, he said, if he tests 20,000 people and finds 2000 infected, he might be able to negotiate to get the cost of a 12-week course reduced by a third to $US1000.
“Where in the US, you get one pill, here you get an entire treatment,” he said. “People in these villages can afford this – possibly everybody can.”
The disease is a topic of conversation for the elders at the tailor’s shop in Lande Rode, a cluster of concrete houses dotting dirt roads and surrounded by rice and wheat fields. Baldev Singh, a farmer and official of the Sikh temple, said he reckoned 80 per cent of the village is infected.
Singh’s family is like many. He was successfully treated with interferon injections last year, before the antiviral pill was available. He looks older than his 45 years, his beard fully gray and his eyes hidden behind sunglasses, even inside the tailor’s dimly lit shop.
His wife, brother and 16-year-old nephew have hepatitis C; the nephew is taking sofosbuvir financed by a loan. But Singh hasn’t had his teenage sons tested yet – and his wife takes an Ayurvedic medicine made whose ingredients include capers and wild chicory. Singh said he thinks her viral count is too low to warrant the expense of generic Sovaldi.
“And anyway,” he said, “the price is supposed to come down a little more, right?”
The Washington Post
This story was found at: http://www.smh.com.au/business/the-drug-that-costs-more-than-1200-and-sells-for-5-in-india-20160103-glya8a.html
Scary to think that this is going on. We know many families that go through the pain of paying for medical supplies. Hopefully the Australian Government helps with these issues in Australia. Learn about blood born virus such as hepatitis in our first aid course in Canberra and how to minimise the chance of infection whilst helping people.